Purdue Sues TWi Over Insomnia Drug Generic Plans

Law360, New York (August 22, 2013, 4:08 PM EDT) -- Purdue Pharma LP on Tuesday sued rival TWi Pharmaceuticals Inc. in New Jersey federal court, claiming a planned generic version of insomnia treatment Intermezzo infringed a pair of patents for the drug licensed to Purdue.

According to Purdue, Taiwanese drugmaker TWi’s planned 1.75- and 3.5-milligram dose sublingual tablet versions of zolpidem tartrate infringe on two patents — U.S. Patent Numbers 8,242,131 and 8,252,809 — covering Intermezzo, exclusively licensed to Purdue by drug development company Transcept Pharmaceuticals Inc.

“Plaintiffs will be irreparably harmed if TWi is not...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.